Blood-Based Biomarkers for Traumatic Brain Injury (TBI)

New Findings from the Transforming Research and Clinical Knowledge (TRACK) in TBI and the Concussion Assessment, Research and Educate (CARE) Consortium Multi Center Teams

Date: Wednesday, July 27th

Time: 7 – 8:30 a.m.

Marriott Marquis, Grand Horizon Ballroom AB

Supported by ABBOTT, Core Diagnostics


Traumatic brain injury (TBI) is a highly prevalent condition that contributes to the overcrowding of emergency departments (ED) worldwide, while also requiring a large proportion of frequently constrained ED resources. Traditional diagnostics tools for the effective triage of TBI patients predominantly rely on the clinical assessment and the use of neuroimaging tools such as computer tomography (CT). Objective blood biomarkers can aid in the diagnosis, triage and prognosis of these patients in the ED. Substantial clinical evidence is available now regarding blood biomarkers such as plasma ubiquitin C-terminal hydrolase- L1 (UCH-L1) and glial fibrillary acidic protein (GFAP). Interpretation from these blood test can help guide decision clinical decisions.


After attending this session, participants will be able to:

  1. Recognize the crucial unmet need for improved brain health assessment
  2. To better understand the diagnostic and prognostic utility of blood-based biomarkers.
  3. Understand how blood-based biomarkers maybe used to help clinicians manage concussion and TBI


Beth McQuiston, MD, RD
Medical Director
ABBOTT, Core Diagnostics
North Chicago, Il


Geoff Manley, MD, PhD
Chief Neurosurgery, Professor and Vice Chairman of Neurological Surgery, Trauma Neurosurgeon and Co-Director of the Brain and Spinal Injury Center
San Francisco, CA

Mike McCrea, PhD, ABPP
Chair in Neurosurgery, Professor: Vice Chair of Research, Co-Director Neurotrauma Research Center: Director, Brain Injury Research Program
Medical College of Wisconsin
Milwaukee, WI